Gerty Schreibelt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2469648/publications.pdf

Version: 2024-02-01

82 papers	5,849 citations	81900 39 h-index	79698 73 g-index
82 all docs	82 docs citations	82 times ranked	7854 citing authors

#	Article	IF	Citations
1	Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients. Cancer Research, 2013, 73, 1063-1075.	0.9	295
2	Dendritic Cellâ€“Based Immunotherapy: State of the Art and Beyond. Clinical Cancer Research, 2016, 22, 1897-1906.	7.0	295
3	Reactive oxygen species alter brain endothelial tight junction dynamics via RhoA, PI3 kinase, and PKB signaling. FASEB Journal, 2007, 21, 3666-3676.	0.5	294
4	Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. Journal of Clinical Investigation, 2011, 121, 3100-3108.	8.2	271
5	Radical changes in multiple sclerosis pathogenesis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 141-150.	3.8	269
6	Bloodâ€“brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis. Brain, 2004, 127, 616-627.	7.6	254
7	Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radical Biology and Medicine, 2008, 45, 1729-1737.	2.9	252
8	Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunology, Immunotherapy, 2010, 59, 1573-1582.	4.2	220
9	The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood, 2012, 119, 2284-2292.	1.4	217
10	Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. Clinical Cancer Research, 2016, 22, 2155-2166.	7.0	211
11	Route of Administration Modulates the Induction of Dendritic Cell Vaccineâ€“Induced Antigen-Specific T Cells in Advanced Melanoma Patients. Clinical Cancer Research, 2011, 17, 5725-5735.	7.0	158
12	Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood, 2013, 121, 459-467.	1.4	154
13	Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology. Brain Research Reviews, 2007, 56, 322-330.	9.0	153
14	Lipoic Acid Affects Cellular Migration into the Central Nervous System and Stabilizes Blood-Brain Barrier Integrity. Journal of Immunology, 2006, 177, 2630-2637.	0.8	144
15	Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunology, Immunotherapy, 2008, 57, 1589-1597.	4.2	141
16	Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cellâ€“Based Vaccination. Cancer Research, 2013, 73, 19-29.	0.9	131
17	The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. , 2019, 7, 109.		129
18	Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets. Frontiers in Immunology, 2014, 5, 165.	4.8	127

#	Article	IF	Citations
19	Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. Frontiers in Immunology, 2018, 9, 2265.	4.8	107
20	Targeting Uptake Receptors on Human Plasmacytoid Dendritic Cells Triggers Antigen Cross-Presentation and Robust Type I IFN Secretion. Journal of Immunology, 2013, 191, 5005-5012.	0.8	98
21	Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines. Cancer Research, 2016, 76, 4332-4346.	0.9	93
22	Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood, 2010, 116, 564-574.	1.4	86
23	Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients. Clinical Cancer Research, 2012, 18, 5460-5470.	7.0	86
24	Proteomics of Human Dendritic Cell Subsets Reveals Subset-Specific Surface Markers and Differential Inflammasome Function. Cell Reports, 2016, 16, 2953-2966.	6.4	72
25	Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer. , 2019, 7, 302.		72
26	NAD(P)H:quinone oxidoreductase 1 expression in multiple sclerosis lesions. Free Radical Biology and Medicine, 2006, 41, 311-317.	2.9	69
27	Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunology, Immunotherapy, 2011, 60, 249-260.	4.2	68
28	Opportunities for immunotherapy in microsatellite instable colorectal cancer. Cancer Immunology, Immunotherapy, 2016, 65, 1249-1259.	4.2	67
29	Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. OncoImmunology, 2016, 5, e1057673.	4.6	67
30	Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Research, 2010, 30, 5091-7.	1.1	67
31	Targeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells. Clinical Cancer Research, 2013, 19, 1525-1533.	7.0	58
32	A Comparative Study of the T Cell Stimulatory and Polarizing Capacity of Human Primary Blood Dendritic Cell Subsets. Mediators of Inflammation, 2016, 2016, 1-11.	3.0	57
33	In situ Expression of Tumor Antigens by Messenger RNAâ€“Electroporated Dendritic Cells in Lymph Nodes of Melanoma Patients. Cancer Research, 2009, 69, 2927-2934.	0.9	56
34	Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. OncoImmunology, 2015, 4, e1019197.	4.6	55
35	Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. OncoImmunology, 2022, 11, .	4.6	54
36	Long Overall Survival After Dendritic Cell Vaccination in Metastatic Uveal Melanoma Patients. American Journal of Ophthalmology, 2014, 158, 939-947.e5.	3.3	53

#	Article	IF	Citations
37	Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cellâ€“Based Vaccination in Metastatic Melanoma. Cancer Research, 2012, 72, 6102-6110.	0.9	50
38	Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. Cancer Immunology, Immunotherapy, 2016, 65, 327-339.	4.2	50
39	Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets. Cancer Immunology, Immunotherapy, 2015, 64, 1461-1473.	4.2	47
40	Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma. Ophthalmology, 2016, 123, 2265-2267.	5.2	44
41	CD1 and Major Histocompatibility Complex II Molecules Follow a Different Course during Dendritic Cell Maturation. Molecular Biology of the Cell, 2003, 14, 3378-3388.	2.1	42
42	Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. Cancer Immunology, Immunotherapy, 2020, 69, 477-488.	4.2	42
43	Immune Curbing of Cancer Stem Cells by CTLs Directed to NANOG. Frontiers in Immunology, 2018, 9, 1412.	4.8	40
44	Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome. Cancer Letters, 2017, 403, 159-164.	7.2	37
45	PLGA-encapsulated perfluorocarbon nanoparticles for simultaneous visualization of distinct cell populations by ¹⁹F MRI. Nanomedicine, 2015, 10, 2339-2348.	3.3	34
46	PTEN Hamartoma Tumor Syndrome and Immune Dysregulation. Translational Oncology, 2019, 12, 361-367.	3.7	33
47	Protective effects of peroxiredoxin-1 at the injured bloodâ€“brain barrier. Free Radical Biology and Medicine, 2008, 45, 256-264.	2.9	32
48	What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings. Cytotherapy, 2020, 22, 388-397.	0.7	29
49	Human pDCs Are Superior to cDC2s in Attracting Cytolytic Lymphocytes in Melanoma Patients Receiving DC Vaccination. Cell Reports, 2020, 30, 1027-1038.e4.	6.4	29
50	Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer. Frontiers in Immunology, 2020, 11, 631713.	4.8	27
51	Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients. Journal of Immunotherapy, 2016, 39, 241-248.	2.4	26
52	Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells. Cancer Immunology, Immunotherapy, 2009, 58, 1109-1115.	4.2	25
53	Crosstalk between dendritic cell subsets and implications for dendritic cell-based anticancer immunotherapy. Expert Review of Clinical Immunology, 2014, 10, 915-926.	3.0	22
54	Primary Human Blood Dendritic Cells for Cancer Immunotherapyâ€”Tailoring the Immune Response by Dendritic Cell Maturation. Biomedicines, 2015, 3, 282-303.	3.2	22

#	Article	IF	Citations
55	Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. OncoImmunology, 2016, 5, e1201625.	4.6	21
56	Reducing cell number improves the homing of dendritic cells to lymph nodes upon intradermal vaccination. OncoImmunology, 2013, 2, e24661.	4.6	20
57	Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. OncoImmunology, 2016, 5, e1191732.	4.6	17
58	Monitoring of dynamic changes in Keyhole Limpet Hemocyanin (KLH)-specific B cells in KLH-vaccinated cancer patients. Scientific Reports, 2017, 7, 43486.	3.3	16
59	Dendritic cell vaccination in melanoma patients: From promising results to future perspectives. Human Vaccines and Immunotherapeutics, 2016, 12, 2523-2528.	3.3	15
60	Naturally produced type I IFNs enhance human myeloid dendritic cell maturation and IL-12p70 production and mediate elevated effector functions in innate and adaptive immune cells. Cancer Immunology, Immunotherapy, 2018, 67, 1425-1436.	4.2	15
61	Immunological responses to adjuvant vaccination with combined CD1c⁺ myeloid and plasmacytoid dendritic cells in stage III melanoma patients. OncoImmunology, 2022, 11, .	4.6	14
62	Recurrent candidiasis and early-onset gastric cancer in a patient with a genetically defined partial MYD88 defect. Familial Cancer, 2016, 15, 289-296.	1.9	13
63	BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?. Vaccines, 2018, 6, 65.	4.4	13
64	Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination. OncoImmunology, 2020, 9, 1738814.	4.6	13
65	Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy. OncoImmunology, 2013, 2, e24440.	4.6	11
66	Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3â€dioxygenase 1 with functional effects on T cell priming. European Journal of Immunology, 2021, 51, 1494-1504.	2.9	11
67	Enterovirus-Infected Î²-Cells Induce Distinct Response Patterns in BDCA1+ and BDCA3+ Human Dendritic Cells. PLoS ONE, 2015, 10, e0121670.	2.5	8
68	Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy. Clinical and Translational Oncology, 2019, 21, 774-780.	2.4	7
69	Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performance. Journal of Immunological Methods, 2018, 458, 74-82.	1.4	5
70	Preventive dendritic cell vaccination in healthy Lynch syndrome mutation carriers. Annals of Oncology, 2016, 27, vi362.	1.2	4
71	High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer. Frontiers in Oncology, 2020, 10, 536700.	2.8	4
72	Early predictive value of multifunctional skin-infiltrating lymphocytes in anticancer immunotherapy. OncoImmunology, 2014, 3, e27219.	4.6	3

#	Article	IF	Citations
73	Challenges of Neoantigen Targeting in Lynch Syndrome and Constitutional Mismatch Repair Deficiency Syndrome. Cancers, 2021, 13, 2345.	3.7	3
74	Natural dendritic cell vaccinations generate immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer. Annals of Oncology, 2019, 30, v480.	1.2	2
75	Myeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients.. Journal of Clinical Oncology, 2018, 36, 219-219.	1.6	2
76	Oxidative Stress in Multiple Sclerosis Pathology and Therapeutic Potential of Nrf2 Activation. , 2011, , 65-77.		1
77	Skin-Test Infiltrating Lymphocytes Predict Clinical Outcome of Dendritic Cell Based Vaccination in Metastatic Melanoma. Annals of Oncology, 2012, 23, ix363.	1.2	0
78	532 Skin infiltrating lymphocytes as an early biomarker to predict clinical outcome in stage III melanoma patients receiving adjuvant dendritic cell vaccination. European Journal of Cancer, 2015, 51, S114-S115.	2.8	0
79	Novel Concepts in Dendritic Cell Vaccination against Cancer. AACR Education Book, 2012, 2012, 61-65.	0.0	0
80	Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Concepts. , 2013, , 71-108.		0
81	Dendritic Cell-Based Cancer Vaccines. , 2014, , 69-87.		0
82	Abstract IA44: Cancer prevention: Dendritic cell enhanced immune responses towards neoantigens in patients with Lynch syndrome. , 2016, , .		0